NORTHRIDGE, Calif., March 6, 2026 /PRNewswire/ -- MiniMed Group, Inc. ((MiniMed, NASDAQ:MMED), a global leader in diabetes management, will begin trading on the Nasdaq Global Select Market (Nasdaq) today under the symbol

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">NORTHRIDGE, Calif.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 6, 2026</span> /PRNewswire/ -- MiniMed Group, Inc. ((MiniMed, NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MMED">MMED</a>), a global leader in diabetes management, will begin trading on the Nasdaq Global Select Market (Nasdaq) today under the symbol &#34;MMED&#34; in connection with its initial public offering (IPO). Members of MiniMed&#39;s leadership team, including Chief Executive Officer Que Dallara, will celebrate this milestone by ringing the Nasdaq&#39;s Opening Bell this morning.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2926457/MiniMed_logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2926457/MiniMed_logo.jpg" title="MiniMed logo" alt="MiniMed logo"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;Today is a defining moment for MiniMed as we begin operating as a standalone, public company,&#34; said Que Dallara, Chief Executive Officer of MiniMed. &#34;For more than 40 years, our mission has been unwavering: to make every day a better day for people with diabetes. Now, with a singular focus and renewed purpose, we&#39;re poised to build on that legacy to shape the future of diabetes care as the only company that commercializes a fully integrated insulin delivery system with connected devices designed to work seamlessly together.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About MiniMed<br xmlns="http://www.w3.org/1999/xhtml"></br></b>MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we&#39;ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Cautions Regarding Forward-Looking Statements  <br xmlns="http://www.w3.org/1999/xhtml"></br></b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO. Important factors that could cause actual results to differ materially from management&#39;s expectations include, without limitation: capital market risks and the impact of general economic or industry conditions. MiniMed&#39;s ability to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside MiniMed&#39;s control. For additional information about the factors that affect MiniMed&#39;s businesses, please see its filings with the SEC. MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA01781&amp;sd=2026-03-06"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/minimed-begins-trading-on-nasdaq-global-select-market-302706724.html" target="_blank">https://www.prnewswire.com/news-releases/minimed-begins-trading-on-nasdaq-global-select-market-302706724.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE MiniMed</p>

MMED

MiniMed begins trading on Nasdaq Global Select Market

MiniMed Group Launches IPO, Begins Trading on Nasdaq as MMED

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NORTHRIDGE, Calif., March 6, 2026 /PRNewswire/ -- MiniMed Group, Inc. ((MiniMed, NASDAQ:MMED), a global leader in diabetes management, will begin trading on the Nasdaq Global Select Market (Nasdaq) today under the symbol</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>MiniMed Group, Inc. commenced trading on Nasdaq today under the symbol MMED following its IPO. The company aims to lead in diabetes management with innovative integrated insulin delivery systems, which may significantly influence its future growth trajectory.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>MiniMed begins trading on Nasdaq under symbol MMED today.</li><li>Company aims for innovation in diabetes management and insulin delivery.</li><li>CEO Que Dallara emphasizes the commitment to improving diabetes care.</li><li>IPO success hinges on market conditions and MiniMed&#039;s business strategy.</li><li>MiniMed&#039;s integrated ecosystem enhances customer experience in insulin delivery.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>MiniMed (MMED)</strong>: With its IPO, MiniMed targets significant growth in diabetes care innovations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The article falls under &#039;Corporate Developments&#039;, as it discusses MiniMed&#039;s IPO launch and market entry. This category is pertinent given its potential to reshape investor perception and market share in the diabetes management sector.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Successful IPO could enhance investor sentiment and drive share price up.</li><li>Market reception will depend on demand for MiniMed&#039;s integrated diabetes solutions.</li><li>Any significant news on product launches or partnerships may further influence pricing.</li><li>Overall market conditions and economic stability remain critical for MMED&#039;s valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>MiniMed&#039;s IPO date is March 6, 2026.</li><li>MiniMed is a global leader in diabetes management with operations in 80 countries.</li><li>CEO Que Dallara led the Nasdaq Opening Bell ceremony today.</li><li>MiniMed emphasizes a fully integrated insulin delivery ecosystem.</li><li>The company has over 40 years in advancing diabetes care technology.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider accumulating MMED shares, anticipating upward price movements as the company establishes market presence.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">NORTHRIDGE, Calif.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">March 6, 2026</span> /PRNewswire/ -- MiniMed Group, Inc. ((MiniMed, NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MMED">MMED</a>), a global leader in diabetes management, will begin trading on the Nasdaq Global Select Market (Nasdaq) today under the symbol &#34;MMED&#34; in connection with its initial public offering (IPO). Members of MiniMed&#39;s leadership team, including Chief Executive Officer Que Dallara, will celebrate this milestone by ringing the Nasdaq&#39;s Opening Bell this morning.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2926457/MiniMed_logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2926457/MiniMed_logo.jpg" title="MiniMed logo" alt="MiniMed logo"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">&#34;Today is a defining moment for MiniMed as we begin operating as a standalone, public company,&#34; said Que Dallara, Chief Executive Officer of MiniMed. &#34;For more than 40 years, our mission has been unwavering: to make every day a better day for people with diabetes. Now, with a singular focus and renewed purpose, we&#39;re poised to build on that legacy to shape the future of diabetes care as the only company that commercializes a fully integrated insulin delivery system with connected devices designed to work seamlessly together.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">A registration statement on Form S-1 relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About MiniMed<br xmlns="http://www.w3.org/1999/xhtml"></br></b>MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we&#39;ve pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Cautions Regarding Forward-Looking Statements  <br xmlns="http://www.w3.org/1999/xhtml"></br></b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the IPO. Important factors that could cause actual results to differ materially from management&#39;s expectations include, without limitation: capital market risks and the impact of general economic or industry conditions. MiniMed&#39;s ability to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside MiniMed&#39;s control. For additional information about the factors that affect MiniMed&#39;s businesses, please see its filings with the SEC. MiniMed does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.</p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA01781&amp;sd=2026-03-06"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/minimed-begins-trading-on-nasdaq-global-select-market-302706724.html" target="_blank">https://www.prnewswire.com/news-releases/minimed-begins-trading-on-nasdaq-global-select-market-302706724.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE MiniMed</p>

MiniMed Group, Inc. commenced trading on Nasdaq today under the symbol MMED following its IPO. The company aims to lead in diabetes management with innovative integrated insulin delivery systems, which may significantly influence its future growth trajectory.

MiniMed begins trading on Nasdaq Global Select Market

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News